
Revolutionizing Cancer Treatment: Exciting Preclinical Results of Reqorsa Gene Therapy to be Unveiled at Prestigious 2024 EORTC-NCI-AACR Symposium
Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma AUSTIN, Texas , Sept. 9, 2024 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that…